You just read:

Inovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)

News provided by

Inovio Pharmaceuticals, Inc.

Feb 10, 2020, 06:00 ET